QR Code

Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers

Abstract Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC), contributing to tumour progression, metastatic dissemination and immune evasion. Hypoxia‐induced angiogenic signalling sustai...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Maria Rosaria Lamia, Erica Perri, Gustavo Baldassarre, Sandro Pignata, Chiara D'Alessio, Davide Limongello, Francesca Basso‐Valentina
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2026-01-01
Rangatū:Clinical and Translational Medicine
Ngā marau:
angiogenesis
bevacizumab
homologous recombination deficiency (HRD)
ovarian cancer
PARP inhibitors
predictive biomarkers
Urunga tuihono:https://doi.org/10.1002/ctm2.70591
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite